BRII-196 and BRII-198 (Investigational)

Brand and Other Names:
    • Print
    Sections

    Dosing & Uses

    COVID-19 (EUA submitted)

    October 9, 2021: Request for emergency use authorization (EUA) initiated for nonhospitalized patients with COVID-19 at risk of clinical progression to severe disease

    Next:

    Pharmacology

    Mechanism of Action

    Non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients

    The antibodies have nonoverlapping epitope binding regions

    Previous
    Next:

    Images

    No images available for this drug.
    Previous
    Next:

    Patient Handout

    A Patient Handout is not currently available for this monograph.
    Previous
    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.